14. Bemerkungen / offene Fragen für die Expertengruppe Off-Label entfällt
15.4 Ergebnisse der systematischen Recherche
(Recherche des Bundesinstituts für Arzneimittel und Medizinprodukte zu Abschnitt 7.a, zusammenfassende Aufstellungen vom 04.12.2017)
Systematische Recherche gemäß Kriterien in Abschnitt 8.
Primäre Prüfung der Fundstellen nach Titel und Abstract mit E: Einschluss von Fundstellen für die weitere Volltextprüfung.
A: Ausschluss (z. B. andere Fragestellung, narrative Arbeiten),
Ausschluss bei Vorliegen von mindestens einem Ausschlussgrund;
bei Vorliegen von mehr als einem Ausschlussgrund in der nachfolgenden Tabelle zu den Ergebnissen der primären Recherche nur Angabe eines Grundes.
29
Nr. Autor/Jahr Titel Recherche Auswertung
1 k.A. (2005) S0307. Phase III trial of
bisphosphonates as adjuvant therapy for primary breast cancer.
Pubmed A
(kein Volltext ermittelbar) 2 k.A. (2005) Zoledronic acid prevents cancer
treatment-induced bone loss.
Pubmed A
(narrative Artikel) 3 k.A. (2006) Comprehensive side-effect profile of
anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial
EMBASE A (andere Fragestellung)
4 Aft et al. (2010) Effect of zoledronic acid on
disseminated tumour cells in women with locally advanced breast cancer:
an open label, randomised, phase 2 trial.
Pubmed A (andere Fragestellung)
5 Aft et al. (2012) Effect of (neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer.
Pubmed A (andere Fragestellung) 6 Allred et al.
(2003)
A roundtable discussion of aromatase inhibitors as therapy for breast cancer
EMBASE A
(narrative Arbeit) 7 Aprile et al.
(2008)
From the podium to the patient:
Bringing the 2008 ASCO meeting to the clinic
EMBASE A
(narrative Arbeit) 8 Et al. (2012)
Benzaïd
In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1
engagement.
Pubmed A (andere Fragestellung)
9 Body (2011) Increased fracture rate in women with breast cancer: a review of the hidden risk.
Pubmed A
(narrative Arbeit) 10 Bošković et al.
(2017)
Bone health and adherence to vitamin D and calcium therapy in early breast cancer patients on endocrine therapy with aromatase inhibitors.
Pubmed A (andere Fragestellung) 11 Brufsky et al.
(2008)
Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone 13loss in
postmenopausal wo14men with early breast cance15r receiving adjuvant letrozole.
Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.
Pubmed, EMBASE
A
(anderer primärer Endpunkt) 13 Brufsky (2006) Management of
cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Pubmed A
(andere Fragestellung) 14 Brufsky et al.
(2012)
Final 5-year results of Z-FAST trial:
adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.
Pubmed,
Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month
Pubmed, EMBASE
E (für
Volltextprüfung)
30 follow-up results.
16 Bundred et al.
(2008)
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
Pubmed,
Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01).
Pubmed,
Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
Pubmed A
(andere Fragestellung)
19 Charehbili et al. (2014)
Addition of zoledronic acid to
neo24adjuvant chemotherap25y does not enhance tumor 26response in patients with HE27R2-negative stage II/III b8reast cancer: the NEOZOTAC trial (BOOG 2010-01).
Pubmed A
(andere Fragestellung)
20 Cheung et al.
(2013)
Breast cancer and osteoporosis. Pubmed A
(narrative Arbeit) 21 Coleman et al.
(2012)
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.
Pubmed,
Safety of zoledronic acid and
incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE:
BIG 01-04) for women with stage II/III breast cancer.
Pubmed.
Breast-cancer adjuvant therapy with zoledronic acid.
Pubmed E
(für
Volltextprüfung) 24 Coleman et al.
(2014)
Adjuvant zoledronic acid in patients with early breast cancer: final efficay analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial
Estrogen-dependent increase in bone turnover and bone loss in
postmenopausal women with breast cancer treated with anastrozole.
Prevention with bisphosphonates.
Pubmed A
(andere Fragestellung)
26 Coveler et al.
(2009)
Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity.
Pubmed A
(andere Fragestellung) 27 Crew et al.
(2009)
High prevalence of vitamin D
deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy
EMBASE A
(andere Fragestellung)
28 Dellapasqua et al. (2007)
New criteria for selecting elderly patients for breast cancer adjuvant treatment studies
EMBASE A
(andere Fragestellung) 29 Desta (2007) Germline pharmacogenetics of EMBASE A
31 tamoxifen response: Have we learned
enough?
(andere Fragestellung) 30 Eidtmann et al.
(2010)
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.
Pubmed,
Skeletal events of Anastrozole versus Tamoxifen on bone mineral density and bone biomarker osteocalcin in postmenopausal women with early breast cancer
EMBASE A
(andere Fragestellung)
32 Fasching et al.
(2014)
FemZone trial: A randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients
EMBASE A
(andere Fragestellung) 33 Fehm (2011) Bisphosphonates: Can they serve as
anti cancer agents in the adjuvant setting?
EMBASE A
(andere Fragestellung) 34 Fox (2010) Adding zoledronic acid to endocrine
therapy in the adjuvant treatment of hormone-sensitive breast cancer in premenopausal women: a new care standard or a provocative idea?
Pubmed) A (andere Fragestellung)
35 Fuleihan et al.
(2005)
Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial.
Pubmed A
(andere Fragestellung) 36 Gligorov et al.
(2003)
Breast cancer symposium: From San Antonio to Saint Gallen
EMBASE A
(andere Fragestellung) 37 Gnant et al.
(2015)
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer:
final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Pubmed, EMBASE
A
(anderes Kollektiv;
prämenopausal)
38 Gnant et al.
(2015)
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre,
randomised, double-blind, placebo-controlled trial.
Pubmed A
(andere Fragestellung) 39 Gnant (2012) Adjuvant bisphosphonates: a new
standard of care?
Pubmed) A
(narrative Arbeit) 40 Gnant et al.
(2011)
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer:
62-month follow-up from the ABCSG-12 randomised trial.
Pubmed A
(anderes Kollektiv;
prämenopausal)
41 Gnant et al.(2009)
Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?
Pubmed A
(andere Fragestellung) 42 Gnant et al.
(2009)
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Pubmed A
(anderes Kollektiv;
prämenopausal) 43 Gnant et al.
(2008)
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer:
5-year follow-up of the ABCSG-12
Pubmed A
(anderes Kollektiv)
32 bone-mineral density substudy
44 Gnant et al.
(2007)
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Pubmed A
(anderes Kollektiv;
prämenopausal
45 Gnant et al.
(2005)
Adjuvant Denosumab in Breast Cancer (ABCSG-18): A Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial
Clincialtrials No.42
A
(anderes Kollektiv;
prämenopausal) 46 Goss et al.
(2014)
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
National Cancer Institute of Canada Clinical Trials Group MAR3 trial:
Evaluation of exemestane to prevent breast cancer in postmenopausal women
EMBASE A (andere Fragestellung)
48 Gralow (2002) Bisphosphonates as adjuvant treatment for breast cancer.
Pubmed A
(narrative Arbeit) 49 Gralow et al.
(2005)
Phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer
Prevention of bone loss with
risedronate in breast cancer survivors:
a randomized, controlled clinical trial.
Pubmed A
(andere Fragestellung) 51 Gregory et al.
(2016)
Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling.
Pubmed A (andere Fragestellung) 52 De Groot et al.
2015)
Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)
EMBASE A
(andere Fragestellung) 53 Hadji et al.
2014
Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
Pubmed, EMBASE
A
(anderes Kollektiv;
prämenopausal)
54 Hadji et al.
2014
Effect of adjuvant endocrine therapy on hormonal levels in premenopausal women with breast cancer: The ProBONE II study
EMBASE A
(anderes Kollektiv;
prämenopausal) 55 Hadji P,
Bundred N.
(2007)
Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
Pubmed A
(Übersichtsarbeit) 56 Hadji (2007) Reducing the risk of bone loss
associated with breast cancer treatment.
Pubmed A
(narrative Arbeit) 57 Hadji (2010) Guidelines for Osteoprotection in
Breast Cancer Patients on an Aromatase Inhibitor
EMBASE A
(narrative Arbeit) 58 Hasegawa et
al. (2015)
Randomized controlled trial of zoledronic acid plus chemotherapy versus chemotherapy alone as neoadjuvant treatment of
HER2-EMBASE A (andere Fragestellung)
33 negative primary breast cancer
(JONIE Study) 59 Hepp et al.
(2016)
Association of CA27.29 and
Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial.
Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment.
Pubmed,
Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer.
Pubmed A
(andere Fragestellung) 62 Hines et al.
(2010)
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.
Pubmed) A (anderer Fragestellung)
63 Hines et al.
(2009)
Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer.
Pubmed A
(andere Fragestellung)
64 Ignatiadis M, Sotiriou C.
(2013)
Luminal breast cancer: from biology to treatment.
Early and accurate prediction of pathological response by magnetic resonance imaging and
ultrasonography in patients undergoing neoadjuvant
chemotherapy for operable breast cancer
EMBASE A (andere Fragestellung)
66 Kalder et al.
(2014)
Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in
premenopausal women with breast cancer treatment-induced bone loss:
results of the ProBONE II substudy
EMBASE A
(andere Fragestellung)
67 Kennedy (1997)
Systemic therapy for breast cancer EMBASE A
(narrative Arbeit) 68 Khan et al.
(2010)
Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer
EMBASE A (andere Fragestellung)
69 Kim et al (2011)
Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01).
Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer.
Pubmed, EMBASE
E (für
Volltextprüfung)
34 71 Lee et al.
(2011)
Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer.
Pubmed A (andere Fragestellung) 73 Lester et al.
(2008)
Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant
aromatase inhibitor therapy for breast cancer.
Immediate Administration of
Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
Pubmed, EMBASE
A (andere Fragestellung;
keine Daten zu Rezidiven) 75 Logman et al.
(2010)
Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK.
Pubmed A (andere Fragestellung)
76 Mahtani R, Jahanzeb M.
(2010)
Bisphosphonates as anticancer therapy for early breast cancer.
Pubmed A
(narrative Arbeit) 77 Mann et al.
2005)
Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen
EMBASE A (andere Fragestellung)
78 McCaig et al.
(2010)
A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
Pubmed) A (andere Fragestellung)
79 Miura et al.
(2013)
Disease-free survival and Ki67 analysis of a randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer
(JONIE-1 study)
EMBASE A
(andere Fragestellung)
80 Mouridsen (1989)
How to improve adjuvant treatment results in postmenopausal patients.
Pubmed A
(Übersichtsarbeit) 81 Neville-Webbe
et al. (2005)
Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells.
Pubmed A (andere Fragestelllung) 82 Nuzzo et al.
(2012)
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study.
Pubmed,
Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone
microenvironment in vivo.
Pubmed A (andere Fragestellung)
35 84 Paterson
(2012)
Oral clodronate for adjuvant treatmemt of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a muticenter, placebo-controlled, randomised trial
In Zusatz-recherchen
E (für
Volltextprüfung)
85 Peppercorn (2009)
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA.17
EMBASE A
(andere Fragestellung)
87 Pfeiler et al.
(2011)
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.
Pubmed A
(anderes Kollektiv;
prämenopausal)
88 Prasad et al.
(2016)
Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial
EMBASE A
(andere Fragestellung) 89 Pritchard et al.
(2006)
The extended adjuvant NCIC CTG MA.17 trials: initial and
rerandomization studies.
Pubmed,
RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy.
Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model.
Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro.
Pubmed A (andere Fragestellung) 93 Rack et al.
(2010)
Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer.
Pubmed A
(andere Fragestellung) 94 Rack et al.
(2008)
[Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer.
A phase II pilot study].
Pubmed A (andere Fragestellung) 95 Ranganathan
et al. (2007)
Meeting Highlights from the 24th Annual Miami Breast Cancer Conference Miami, FL March 14-17, 2007
EMBASE A
(narrative Arbeit)
96 Rathbone et al.
(2013)
Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04).
Pubmed E (für
Volltextprüfung)
97 Reid et al.
(2008)
Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Pubmed A
Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients
Pubmed, EMBASE
A (andere Fragestellung)
36 with early breast cancer: the HOBOE
trial.
99 Rossi et al.
(2008)
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer nein receiving adjuvant letrozole: ZO-FAST study results
EMBASE A
(andere Fragestellung)
100 Rossi et al.
(2008)
Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cance
EMBASE A
(andere Fragestellung) 101 Ruddy et al.
(2014)
Extended therapy with letrozole and ovarian suppression in
premenopausal patients with breast cancer after tamoxifen.
Pubmed
Cancer treatment-induced bone loss in breast and prostate cancer.
Pubmed A
(Übersichtsarbeit) 103 Saarto et al.
(2008)
Three-year oral clodronate treatment does not impair mineralization of newly formed bone - A
histomorphometric study
EMBASE A (andere Fragestellung) 104 Saarto et al.
(1998)
Aminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and post-menopausal non-metastatic breast cancer patients
EMBASE A (andere Fragestellung)
105 Saarto et al.
(1997)
Clodronate improves bone mineral density in postmenopausal breast cancer patients treated with adjuvant antioestrogens
Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer.
Pubmed) E (für
Volltextprüfung) 107 Saarto et al.
(2001)
The effect of clodronate and antioestrogens on bone loss
associated with oestrogen withdrawal in postmenopausal women with breast cancer.
Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.
Pubmed, EMBASE
A
(anderes Kollektiv;
prämenopausal)
109 Sugie et al.
(2013)
Zoledronic acid-induced expansion of γδ T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells.
Pubmed A (andere Fragestellung 110 Sun et al.
(2016)
Preventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole
Physical activity in women receiving chemotherapy for breast cancer:
adherence to a walking intervention.
Pubmed A (andere Fragestellung) 112 Tan, Wolff
(2007)
Luteinizing hormone-releasing hormone agonists in premenopausal
EMBASE A
(andere
37 hormone receptor-positive breast
cancer
Fragestellung) 113 Takahashi et
al. (2012)
Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results.
Pubmed A (andere Fragestellung) 114 Tang (2010) Women and bone health: maximizing
the benefits of aromatase inhibitor therapy.
The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer.
The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors:
a 2-year trial.
Lipid profiles within the SABRE trial of anastrozole with and without
risedronate.
Prevention of aromatase inhibitor-induced bone loss using risedronate:
the SABRE trial.
Pubmed,
Breast-cancer adjuvant therapy with zoledronic acid Van Poznak C
EMBASE A
(Kommentar, narrative) 120 Vehmanen et
al. (2004)
Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure
Pubmed A
(andere Fragestellung) 121 Vehmanen et
al. (2004)
Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids.
Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment.
Pubmed A
(andere Fragestellung)
123 Wachter (2011) Zoledronic acid sinks as stage II/III therapy in AZURE trial
EMBASE A
(Pressemitteilung) 124
Wagner-Johnston et al.
(2015)
5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in
postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
Pubmed A
(andere Fragestellung)
125 Welton et al.
(2013)
γδ T cells predict outcome in zoledronate-treated breast cancer patients.
The differential anti-tumour effects of zoledronic acid in breast cancer - evidence for a role of the activin signaling pathway.
Pubmed A (andere Fragestellung) 127 Winter (2009) Zoledronic acid (Zometa) plus
neoadjuvant chemotherapy have antitumor activity
EMBASE A (andere Fragestellung)
38 128 Zhou et al.
(2011)
Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer treatment: a meta-analysis.
Pubmed A
(andere Fragestellung)
Recherche nach Meta-Analysen
Nr. Autor/Jahr Titel Recherche Auswertung
1 Abdel-Rahman et al. (2016)
Denosumab versus zoledronic acid to prevent aromatase
inhibitors-associated fractures in
postmenopausal early breast cancer;
a mixed treatment meta-analysis.
Pubmed A
(andere Fragestellung)
2 Kroep et al.
(2016)
Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials.
Pubmed A
(andere Fragestellung) 3 EBCTCG
(2015)
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from
randomised trials.
Pubmed E
(für
Volltextprüfung) 4 Ben-Aharon
(2013)
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis.
Pubmed E
(für
Volltextprüfung) 5 Valachis et al.
(2010)
Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: a meta-analysis.
Pubmed A
(andere Fragestellung)